Feature | September 09, 2014

Quadripolar Lead Trumps Bipolar Option in MORE-CRT Trial Presented at ESC


September 9, 2014 — Use of a quadripolar left ventricular (LV) lead instead of a bipolar option during cardiac resynchronization therapy (CRT) can decrease complications at six months, according to preliminary hot line results presented at the 2014 European Society of Cardiology (ESC) Congress in Barcelona.

The MORE-CRT (More Options available with a quadripolar LV lead pRovidE in-clinic solutions to CRT challenges) trial “demonstrates the safety and efficiency of the quadripolar lead technology in providing more options to manage CRT patients,” said the study’s lead investigator Giuseppe Boriani, M.D., Ph.D., University of Bologna, Italy.

CRT is a well-proven therapy for heart failure patients, who have benefitted for years with bipolar technology. Quadripolar technology is an important new advance for CRT systems that give physicians more programming options to improve patients’ response to CRT therapy and to minimize potential complications.

The CRT device is implanted under the skin with leads going into the heart. “However, in up to 10 percent of heart failure patients LV lead placement is not successful because of anatomical challenges, phrenic nerve stimulation or poor electrical measurements,” said Boriani. “Quadripolar pacing was developed with the aim of overcoming some of these barriers, but until now it has never been tested in a large, prospective, randomized trial.”

The MORE-CRT study included 1,068 heart failure patients scheduled for CRT from 63 centers in 13 countries. Patients aged approximately 68 years were randomized in a 1:2 ratio to undergo CRT with either a bipolar lead (controls; n=348) or a quadripolar lead (n=720).

The study showed that at six months, compared to controls, patients with quadripolar leads were significantly more likely to be free from a composite endpoint of both intra- and post-operative LV lead-related complications (85.97 percent versus 76.86 percent, P=0.0001) – a relative risk reduction (RRR) of 40.8 percent.

The driver of this benefit was mainly intra-operative complications, which were reduced by more than 50 percent in the quadripolar group (5.98 percent vs 13.73 percent, P<0.0001, RRR 56.4 percent), said Boriani.

There were also fewer post-operative complications in the quadripolar group, but the difference was not statistically significant. “The quadripolar lead provides more options to effectively manage common pacing complications, as compared to systems based on bipolar leads; hence, improving the efficiency of CRT,” concluded Boriani.

For more information: www.escardio.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now